| Title |
Naujausi kraujo biožymenys pirminėje prevencinėje kardiologijoje ir jų vertė perklasifikuojant kardiovaskulinę riziką |
| Translation of Title |
Novel blood biomarkers in primary preventive cardiology and their value in cardiovascular risk reclassification. |
| Authors |
Naktinytė, Eva ; Zupkauskienė, Jūratė |
| DOI |
10.53453/ms.2026.7.5 |
| Full Text |
|
| Is Part of |
Medicinos mokslai = Journal of medical science.. Kėdainiai : VšĮ "Lietuvos sveikatos mokslinių tyrimų centras". 2026, vol. 14, iss. 5, p. 32-41.. ISSN 2345-0592. eISSN 2345-0592 |
| Keywords [eng] |
cardiovascular diseases ; biomarkers ; primary prevention ; risk assessment |
| Abstract [eng] |
Introduction. Cardiovascular disease (CVD) remains the leading cause of global mortality, with atherosclerosis typically progressing asymptomatically for decades. Traditional CVD risk scores are valuable but have limited accuracy at the individual level, particularly for patients at borderline risk. Novel blood biomarkers may complement traditional scores and improve CVD risk stratification. Aim of the study. To review recent blood biomarkers investigated in the context of primary preventive cardiology and to evaluate their value in reclassifying CVD risk. Methods. A literature search was performed in PubMed, Embase, and the Cochrane Library, covering English-language publications from 2021 to 2026. Preference was given to original studies assessing the association of blood biomarkers with CVD risk in primary prevention populations. Results. Several biomarker groups were reviewed: lipid and lipoprotein markers, markers of insulin resistance and cardiometabolic dysfunction, systemic inflammation markers, plasma proteomic and metabolomic profiling, and ketone bodies. In the most recent 2025–2026 international guidelines, lipoprotein (a) and high sensitivity C-reactive protein have been recognized as CVD risk modifiers. The addition of most individual biomarkers to traditional risk scores yields modest improvements in discrimination, although reclassification benefits for borderline-risk individuals may be clinically meaningful. Conclusions. Novel blood biomarkers provide additional prognostic information beyond that offered by traditional risk scores. Their greatest value likely lies not in universal screening but in targeted application - reclassification of borderline-risk patients. Broader clinical implementation will require further prospective studies in ethnically diverse populations and cost-effectiveness validation. |
| Published |
Kėdainiai : VšĮ "Lietuvos sveikatos mokslinių tyrimų centras" |
| Type |
Journal article |
| Language |
Lithuanian |
| Publication date |
2026 |
| CC license |
|
